Misplaced Pages

Gefapixant

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Gefapixant
Clinical data
Trade namesLyfnua
Other namesMK-7264
ATC code
Legal status
Legal status
  • EU: Rx-only
Identifiers
IUPAC name
  • 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.258.106 Edit this at Wikidata
Chemical and physical data
FormulaC14H19N5O4S
Molar mass353.40 g·mol
3D model (JSmol)
SMILES
  • CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
InChI
  • InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
  • Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor.

It was approved for medical use in the European Union in September 2023.

Medical uses

Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.

Society and culture

Names

It was named in honour of Geoff Burnstock.

References

  1. ^ "Lyfnua EPAR". European Medicines Agency. 29 September 2023. Retrieved 5 October 2023.
  2. Muccino D, Green S (June 2019). "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics. 56: 75–78. doi:10.1016/j.pupt.2019.03.006. PMID 30880151. S2CID 81982653.
  3. Richards D, Gever JR, Ford AP, Fountain SJ (July 2019). "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology. 176 (13): 2279–2291. doi:10.1111/bph.14677. PMC 6555852. PMID 30927255.
  4. Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents. 29 (12): 943–963. doi:10.1080/13543776.2019.1693542. hdl:11581/435751. PMID 31726893. S2CID 208037373.
  5. Ford AP, Dillon MP, Kitt MM, Gever JR (November 2021). "The discovery and development of gefapixant". Autonomic Neuroscience. 235: 102859. doi:10.1016/j.autneu.2021.102859. PMID 34403981. S2CID 236524967.
Cough and cold preparations (R05)
Expectorants
Mucolytics
Cough suppressants
Opium alkaloids,
opioids,
and derivatives
Other
Portal:


Stub icon

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

Categories: